Skip to main content
. 2019 Dec 3;11:10205–10214. doi: 10.2147/CMAR.S222224

Figure 3.

Figure 3

(A) Western blot analysis of BCL-2 expression in OVCAR-3-Vector cells, OVCAR-3-B7-H3 OE cells and OVCAR-3-B7-H3-OE cells treated with LY294002 (15 μM) or MK-2206 (0.5 μM). (B) Western blot analysis of BCL-2 expression in A2780-Vector cells, A2780-B7-H3 OE cells and A2780-B7-H3 OE cells treated with LY294002(15 μM) or MK-2206(0.5 μM). (C) Western blot analysis of BCL-2 expression in NC (OVCAR-3-pB7-H3) cells, OVCAR-3-pB7-H3-BCL-2 KO cells. (D) Western blot analysis of BCL-2 expression in NC (A2780-pB7-H3) cells, A2780-pB7-H3-BCL-2 KO cells. (E) OVCAR-3-Vector cells, OVCAR-3-pB7-H3 cells and OVCAR-3-pB7-H3-BCL-2 KO cells were treated with 50 μM CIS for 30 hrs. Then, the cells were tested for apoptosis by FCM. Mean ± SEM, n = 3. (F) A2780-Vector cells, A2780-pB7-H3 cells and A2780-pB7-H3-BCL-2 KO cells were treated with 50μM CIS for 30 hrs. Then, the cells were tested for apoptosis by FCM. Mean ± SEM, n = 3. *p < 0.05; ns, not significant.

Abbreviations: NC, negative control; CIS, cisplatin.